Comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Multiplex analysis allows measurements of a large number of analytes simultaneously in each sample. On the basis of the Luminex multiplex technology (xMAP), kits for measuring multiple cytokines and chemokines (immunomodulators) are commercially available and are useful in investigations on inflammatory diseases. This study evaluated four multiplex kits (Bio-Plex, LINCOplex, Fluorokine, and Beadlyte) that contained 27, 29, 20, and 22 analytes each, respectively, for the analysis of immunomodulators in plasma of patients with rheumatoid arthritis (RA) who underwent treatment with antibody against CD20 (rituximab), a B-cell reductive therapy. Methods: Multiplex kits were tested on serial plasma samples obtained from six RA patients at baseline and multiple time points (3, 6, and 9 months) post-treatment with rituximab. The RA patients included in this study had previously failed therapy with disease modifying anti-arthritis drugs (DMARD) and treatment with anti-TNFα antibody (infliximab). Results: Computer modeling and hierarchical cluster analysis of the multiplex data allowed a comparison of the performance of multiplex assay kits and revealed profiles of immunomodulators in the RA patients. Conclusions: In plasma of RA patients who appeared to have benefited from the rituximab treatment, the profile of significantly elevated immunomodulators by at least two of the three kits (BioPlex, LINCOplex, Beadlyte) is as follows: IL-12p70, Eotaxin, IL-4, TNFα, II-9, IL-1β, IFNγ, IL-10, IL-6, and IL-13. Immunomodulator profiling by multiplex analysis may provide useful plasma biomarkers for monitoring response to B-cell reductive therapy in RA patients.

Original languageEnglish (US)
Pages (from-to)159-168
Number of pages10
JournalCytometry Part B - Clinical Cytometry
Volume76
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Chemokines
Immunologic Factors
Rheumatoid Arthritis
Suspensions
Cytokines
Cell- and Tissue-Based Therapy
B-Lymphocytes
Therapeutics
Interleukin-13
Interleukin-1
Interleukin-4
Interleukin-10
Arthritis
Cluster Analysis
Anti-Idiotypic Antibodies
Interleukin-6
Biomarkers
Technology
Pharmaceutical Preparations
Rituximab

Keywords

  • Chemokines
  • Cytokines
  • Luminex
  • Multiplex suspension array
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Cell Biology
  • Histology
  • Pathology and Forensic Medicine

Cite this

@article{a172029ca86b4ac9b35fa615cbf6a62f,
title = "Comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients",
abstract = "Background: Multiplex analysis allows measurements of a large number of analytes simultaneously in each sample. On the basis of the Luminex multiplex technology (xMAP), kits for measuring multiple cytokines and chemokines (immunomodulators) are commercially available and are useful in investigations on inflammatory diseases. This study evaluated four multiplex kits (Bio-Plex, LINCOplex, Fluorokine, and Beadlyte) that contained 27, 29, 20, and 22 analytes each, respectively, for the analysis of immunomodulators in plasma of patients with rheumatoid arthritis (RA) who underwent treatment with antibody against CD20 (rituximab), a B-cell reductive therapy. Methods: Multiplex kits were tested on serial plasma samples obtained from six RA patients at baseline and multiple time points (3, 6, and 9 months) post-treatment with rituximab. The RA patients included in this study had previously failed therapy with disease modifying anti-arthritis drugs (DMARD) and treatment with anti-TNFα antibody (infliximab). Results: Computer modeling and hierarchical cluster analysis of the multiplex data allowed a comparison of the performance of multiplex assay kits and revealed profiles of immunomodulators in the RA patients. Conclusions: In plasma of RA patients who appeared to have benefited from the rituximab treatment, the profile of significantly elevated immunomodulators by at least two of the three kits (BioPlex, LINCOplex, Beadlyte) is as follows: IL-12p70, Eotaxin, IL-4, TNFα, II-9, IL-1β, IFNγ, IL-10, IL-6, and IL-13. Immunomodulator profiling by multiplex analysis may provide useful plasma biomarkers for monitoring response to B-cell reductive therapy in RA patients.",
keywords = "Chemokines, Cytokines, Luminex, Multiplex suspension array, Rheumatoid arthritis",
author = "Imran Khan and Krishnan, {Viswanathan V} and Melanie Ziman and Kim Janatpour and Theodore Wun and Luciw, {Paul A} and Joseph Tuscano",
year = "2009",
doi = "10.1002/cyto.b.20452",
language = "English (US)",
volume = "76",
pages = "159--168",
journal = "Cytometry Part B - Clinical Cytometry",
issn = "1552-4949",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients

AU - Khan, Imran

AU - Krishnan, Viswanathan V

AU - Ziman, Melanie

AU - Janatpour, Kim

AU - Wun, Theodore

AU - Luciw, Paul A

AU - Tuscano, Joseph

PY - 2009

Y1 - 2009

N2 - Background: Multiplex analysis allows measurements of a large number of analytes simultaneously in each sample. On the basis of the Luminex multiplex technology (xMAP), kits for measuring multiple cytokines and chemokines (immunomodulators) are commercially available and are useful in investigations on inflammatory diseases. This study evaluated four multiplex kits (Bio-Plex, LINCOplex, Fluorokine, and Beadlyte) that contained 27, 29, 20, and 22 analytes each, respectively, for the analysis of immunomodulators in plasma of patients with rheumatoid arthritis (RA) who underwent treatment with antibody against CD20 (rituximab), a B-cell reductive therapy. Methods: Multiplex kits were tested on serial plasma samples obtained from six RA patients at baseline and multiple time points (3, 6, and 9 months) post-treatment with rituximab. The RA patients included in this study had previously failed therapy with disease modifying anti-arthritis drugs (DMARD) and treatment with anti-TNFα antibody (infliximab). Results: Computer modeling and hierarchical cluster analysis of the multiplex data allowed a comparison of the performance of multiplex assay kits and revealed profiles of immunomodulators in the RA patients. Conclusions: In plasma of RA patients who appeared to have benefited from the rituximab treatment, the profile of significantly elevated immunomodulators by at least two of the three kits (BioPlex, LINCOplex, Beadlyte) is as follows: IL-12p70, Eotaxin, IL-4, TNFα, II-9, IL-1β, IFNγ, IL-10, IL-6, and IL-13. Immunomodulator profiling by multiplex analysis may provide useful plasma biomarkers for monitoring response to B-cell reductive therapy in RA patients.

AB - Background: Multiplex analysis allows measurements of a large number of analytes simultaneously in each sample. On the basis of the Luminex multiplex technology (xMAP), kits for measuring multiple cytokines and chemokines (immunomodulators) are commercially available and are useful in investigations on inflammatory diseases. This study evaluated four multiplex kits (Bio-Plex, LINCOplex, Fluorokine, and Beadlyte) that contained 27, 29, 20, and 22 analytes each, respectively, for the analysis of immunomodulators in plasma of patients with rheumatoid arthritis (RA) who underwent treatment with antibody against CD20 (rituximab), a B-cell reductive therapy. Methods: Multiplex kits were tested on serial plasma samples obtained from six RA patients at baseline and multiple time points (3, 6, and 9 months) post-treatment with rituximab. The RA patients included in this study had previously failed therapy with disease modifying anti-arthritis drugs (DMARD) and treatment with anti-TNFα antibody (infliximab). Results: Computer modeling and hierarchical cluster analysis of the multiplex data allowed a comparison of the performance of multiplex assay kits and revealed profiles of immunomodulators in the RA patients. Conclusions: In plasma of RA patients who appeared to have benefited from the rituximab treatment, the profile of significantly elevated immunomodulators by at least two of the three kits (BioPlex, LINCOplex, Beadlyte) is as follows: IL-12p70, Eotaxin, IL-4, TNFα, II-9, IL-1β, IFNγ, IL-10, IL-6, and IL-13. Immunomodulator profiling by multiplex analysis may provide useful plasma biomarkers for monitoring response to B-cell reductive therapy in RA patients.

KW - Chemokines

KW - Cytokines

KW - Luminex

KW - Multiplex suspension array

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=66949115247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949115247&partnerID=8YFLogxK

U2 - 10.1002/cyto.b.20452

DO - 10.1002/cyto.b.20452

M3 - Article

C2 - 18823005

AN - SCOPUS:66949115247

VL - 76

SP - 159

EP - 168

JO - Cytometry Part B - Clinical Cytometry

JF - Cytometry Part B - Clinical Cytometry

SN - 1552-4949

IS - 3

ER -